BioSpace News Archive

The global pharmaceutical membrane filtration market is envisaged to gain a strong impetus on the back of regulatory obligations on the part of cleanrooms in pharmaceutical production and improving growth of the generics market.

Zealand Pharma A/S a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced that it will host a conference call on May 12, 2021 at 4 pm CET following the announcement of results for the first quarter of 2021

Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis.

Cellares Corporation, a life sciences technology company that automates cell therapy manufacturing, announced it has secured $82 million in a Series B round, bringing total funding to date to $100 million.

Technology Innovation Institute, the applied research pillar of Advanced Technology Research Council, announced that its Directed Energy Research Centre has partnered with Germany’s Ruhr University Bochum and Helmut Schmidt University, France’s University Clermont Auvergne and National University of Colombia, Bogota.

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today research revealing six novel gene-disease associations for a wide range of genetic disorders and confirmation of 31 additional candidate genes

IVERIC bio, Inc. announced financial and operating results for the quarter ended March 31, 2021 and provided a general business update.

Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that the first patient has been treated in the company’s Phase 2/3 pivotal trial evaluating ADG20 for the prevention of COVID-19, known as the EVADE trial.

Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital.

SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in the BofA (Bank of America) Securities 2021 Virtual Health Care Conference taking place May 11-13, 2021